AbbVie (ABBV) return on equity (ROE)

Return on equity · fiscal 2024
128.7%

AbbVie (ABBV) earned a return on equity of 128.7% in fiscal 2024 (the year ended December 31, 2024). That is 81.7 percentage points higher than the 46.9% of fiscal 2023. Figures as of 17 Nov 2026, 22:28 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2024
128.7%
Change on fiscal 2023
+81.7 pts
Highest on record
130.4%fiscal 2015
Lowest on record
35.3%fiscal 2020
Fiscal years on record
92014–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

AbbVie return on equity (ROE), in more detail

Across the 9 fiscal years on record (2014–2024), the highest was 130.4% in fiscal 2015 and the lowest 35.3% in fiscal 2020. The fiscal 2024 figure is higher than in 88% of the 8 earlier fiscal years on record, whose median is 88.4%.

History · 9 fiscal years

Return on equity by fiscal year

AbbVie return on equity (ROE), year by year

AbbVie (ABBV) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2024128.7% 81.7 pts up
202346.9% 21.7 pts down
202268.6% 6.3 pts down
202174.9% 39.6 pts up
202035.3%—
2017104.2% 24.2 pts down
2016128.4% 2.0 pts down
2015130.4% 28.6 pts up
2014101.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on ABBV

AbbVie, figure by figure

AbbVie (ABBV) overview: price, valuation and scorecardAll health care companies by market value

AbbVie return on equity (ROE): questions and answers

What is AbbVie's return on equity?

AbbVie (ABBV) earned a return on equity of 128.7% in fiscal 2024 (the year ended December 31, 2024). That is 81.7 percentage points higher than the 46.9% of fiscal 2023.

Is AbbVie's return on equity high or low compared with its own history?

The fiscal 2024 figure is higher than in 88% of the 8 earlier fiscal years on record, whose median is 88.4%.

What are the highest and lowest return on equity figures on record for AbbVie?

Across the 9 fiscal years on record (2014–2024), the highest was 130.4% in fiscal 2015 and the lowest 35.3% in fiscal 2020.

How is AbbVie's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “AbbVie (ABBV) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ABBV/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.